STERIS Reports 11% Earnings Growth as Company Unveils $600M Manufacturing Investment
The sterilization and infection prevention specialist maintained its full-year outlook while announcing its largest-ever single-site investment in North Carolina.
Strong Quarter Amid Manufacturing Expansion
STERIS plc reported first-quarter fiscal 2027 results that exceeded prior-year performance, with adjusted earnings per diluted share climbing 11% to $2.59 (earnings call, 2026-08-06). The medical device sterilization and infection prevention company also announced its largest-ever capital investment: a $600 million formulated chemistry manufacturing center in North Carolina.
Total revenue grew 7% on a reported basis, while constant currency organic revenue increased 6%, driven by volume gains and 190 basis points of pricing (earnings call, 2026-08-06). The company's gross margin expanded 70 basis points to 46%, benefiting from pricing discipline and productivity improvements that offset inflationary pressures.
Healthcare Segment Drives Growth
The Healthcare segment delivered 6% constant currency organic revenue growth, with particular strength in services, which grew 10% (earnings call, 2026-08-06). Consumables posted 9% growth, benefiting from increased customer consumption driven by share gains and procedural growth in endoscopy, according to President and CEO Dan Carestio.
Healthcare capital equipment revenue increased just 1%, affected by shipment timing, though orders grew 4% and backlog swelled to $444 million (earnings call, 2026-08-06). Carestio expressed confidence in full-year capital equipment performance, noting "we're reaping the benefits of the last year and half of solid capital sales."
AST Faces Inventory Headwinds
The Applied Sterilization Technologies (AST) segment grew constant currency organic revenue 5%, with services up 6% (earnings call, 2026-08-06). However, volume remained light as customers continued managing down existing inventory against difficult year-over-year comparisons. Carestio indicated the company expects acceleration in the second half as comparisons ease, noting "nothing has changed in the fundamentals."
Historic Chemistry Investment
The announced North Carolina facility represents STERIS's "largest investment in our history in a single manufacturing site," comprising two facilities totaling 600,000 square feet (earnings call, 2026-08-06). The center will produce infection prevention and contamination control chemistries for healthcare and pharmaceutical customers, supporting businesses that collectively generate over $700 million in revenue.
The facility is expected to become operational in 2-3 years through a phased approach and will ultimately consolidate operations from St. Louis, Missouri and Plymouth, Minnesota sites (earnings call, 2026-08-06). Management projects a return on invested capital exceeding 10% within 3-5 years of opening.
The company announced a related restructuring program with anticipated pretax charges of $55 million to $70 million, though less than $10 million is expected to impact fiscal 2027 (earnings call, 2026-08-06).
Outlook and Capital Allocation
STERIS maintained its full-year fiscal 2027 guidance, projecting reported revenue growth of 7-8% and earnings per share of $11.10 to $11.30, representing 9-11% growth (earnings call, 2026-08-06). However, capital expenditures are now expected to reach approximately $450 million, up $75 million due to the North Carolina project.
Free cash flow guidance was adjusted to $800 million from a higher previous expectation, as strong first-quarter performance helps offset the additional capital spending (earnings call, 2026-08-06). The company repurchased $100 million in shares during the quarter and announced its 21st consecutive annual dividend increase to $0.69 per quarter.
This article was generated by MarginX from the earnings call on 2026-08-06. It is not investment advice.